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Abstract: Pancreatic cancer is one of the deadliest causes of cancer-related death in the United
States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical
attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent
for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and
experimental investigations have demonstrated that a combination or co-administration of other
drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination
therapies often induce severe systemic toxicities. Thus, developing strategies to deliver a combination
of chemotherapeutic agents more securely to patients is needed. Nanoparticle-mediated delivery can
offer to load a cocktail of drugs, increase stability and availability, on-demand and tumor-specific
delivery while minimizing chemotherapy-associated adverse effects. This review discusses the
available drugs being co-administered with GEM and the limitations associated during the process
of co-administration. This review also helps in providing knowledge of the significant number of
delivery platforms being used to overcome problems related to gemcitabine-based co-delivery of other
chemotherapeutic drugs, thereby focusing on how nanocarriers have been fabricated, considering
the modes of action, targeting receptors, pharmacology of chemo drugs incorporated with GEM,
and the differences in the physiological environment where the targeting is to be done. This review
also documents the focus on novel mucin-targeted nanotechnology which is under development for
pancreatic cancer therapy.
Keywords: Gemcitabine; chemotherapy; nanoparticles; drug resistance; combination therapy
1. Introduction
Pancreatic cancer (PanCa) is the fourth highest cause among cancer-related deaths (56,770 people,
29,940 men, and 26,830 women) in 2018 in the United States. It was also estimated that about 23,800 men
and 21,950 women were diagnosed with this disease. PanCa accounts for only ~3% of all cancers but
it contributes ~7% of cancer deaths. PanCa accounts for very poor overall median survival, i.e., 5 to
6 months. The 5-year survival rate for patients with pancreatic cancer is only 6 to 8% [1]. This type of
malignant neoplasm occurs from the mucosa of the pancreas ductal epithelium which could be due to
pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasm (MCN), intraductal papillary
mucinous neoplasm (IPMN), and invasive ductal adenocarcinoma. Pancreatic ductal adenocarcinoma
(PDAC) is considered as the most common pathological type of pancreatic cancer and contributes to
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94% of pancreatic cancers [2]. The literature has revealed that patients with pancreatic cancer were
often observed with 90% KRAS mutations, 50 to 80% inactivating mutations in CDKN2A, SMAD4,
and TP53 [3]. Diagnosis of pancreatic cancer at an early stage is highly challenging due to the lack
of medically known urgent symptoms. Surgical resection of tumors is only possible in the case of
localized tumors in the pancreas [3]. Unfortunately, by the time of diagnosis, many patients experience
either a locally advanced stage or distant metastasis, and then become ineligible candidates for surgical
operative procedures. This happens in a majority of patients, thus there is a high priority to manage
disease progression while promoting quality of lifespan. In such a scenario, chemotherapy along
with surgery is a potentially useful and highly preferred curative approach. Patients with advanced
pancreatic cancer refractory status to first-line therapy have a dismal prognosis and limited therapeutic
options, with only one option pertaining to nanoliposome irinotecan in combination with fluorouracil
and folic acid which was approved by FDA based upon results of a phase III NAPOLI-1 study [4].
Clinical activity of Gemcitabine has been progressively seen in non-small cell lung cancer, head and
neck cancer, colon cancer, breast cancer, and pancreatic cancer. According to the report generated
by the NCI (National Cancer Institute) studies are still ongoing in monitoring Gemcitabine as a
potential inhibitor of cancer. In 833 locations, GEM is given in combination with Pemetrexed and it
is believed that the addition of ramucirumab and pembrolizumab will enhance patient survival by
inhibiting tumor growth [5]. Another ongoing study on PANOVA-3 is being carried out on 12 locations;
PANOVA-3 is in a phase III clinical trial which altogether consists of tumor treating fields (TTFs) which
involves use of specific frequencies of the electric field which cause disruption of cell division. In this
trial, TTFs are used in combination with GEM and nab-PTX for treating PanCa [6]. Therefore, in this
review, we present an in-depth analysis of the various combinational studies of Gemcitabine and
evaluate their superior roles with respect to treatment options. This review also provides possible
advanced nanotechnology combination options for future investigations.
2. Gemcitabine—A Gold Standard Chemotherapeutic Agent for Pancreatic Cancer
Chemotherapy is expected to provide substantial local control and prolong survival. However,
there is no efficient and standard treatment for advanced and metastatic pancreatic cancer. Gemcitabine,
a deoxycytidine nucleoside analog (2′-deoxy-2′,2′-difluorocytidine; dFdC), has shown a broad spectrum
of anticancer activity against various tumors, including pancreatic, lung, and breast cancers. GEM
activity depends on its entry into cells and immediate phosphorylation by deoxycytidine kinase (DCK)
takes place which results in monophosphate and diphosphate (dFdCDP) [7,8]. The anticancer activity
results from diphosphate due to the inhibition of ribonucleotide reductase. Triphosphate metabolite
(dFdCTP) is another active metabolite of GEM which can get incorporated into DNA. It locks DNA
polymerase and causes DNA chain termination which is required for DNA synthesis [9].
Gemcitabine as a chemotherapeutic agent is not instantaneous due to severe systemic side effects.
For example, a phase I trial with a maximum dose of 9 mg/m2 five times daily led to fever and fatal
hypotension while a phase II trial (150 mg/m2 twice weekly) showed flu, fever, rigors, and malaise as
its side effects which led towards the withdrawal of GEM [10]. Dissatisfactory results obtained from
the failed trials led towards another set of phase I trials with once a week or once every two weeks drug
infusions (790 mg/m2/week) which resulted in positive activity with minor side effects [11]. Subsequent
positive outcomes of clinical trials of GEM led to the approval of this molecule as a potential anticancer
agent by the FDA (08/04/2011).
GEM is considered a gold-standard treatment for pancreatic cancer. It has also exhibited a broad
spectrum of anticancer activity against various cancers. However, chemoresistance is one of the leading
problems associated with this drug. To overcome the side effects caused by GEM, it has been formulated
in other forms for effective administration and therapeutic outcome. Problems associated with GEM
therapy also opened platforms to administer drugs such as OXA, CIS, and other chemotherapeutic
drugs to be administered with GEM, which are being successfully used at the clinical level, as described
later in the article.
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2.1. Gemzar
Gemzar® is a hydrochloride salt of GEM being produced by Eli Lilly which is extensively used
against pancreatic cancer both as a single therapeutic agent and in combination with many other
anticancer agents. Although it is not immediately life-threatening but Gemzar induces numerous
side effects such as pale skin, easy bruising or bleeding, numbness, tingly feeling, weakness, nausea,
vomiting, stomach upset, diarrhea, constipation, headache, swelling in hands/ankles/feet, skin rash,
drowsiness, and hair loss [12].
The major drawback associated with the delivery of Gemzar is the formation of inactive metabolite
difluorodeoxyuridine in the presence of enzyme deoxycytidine deaminase which exists abundantly in
the liver and blood. Deoxycytidine monophosphatase causes deamination and conversion of Gemzar
to its diphosphate and triphosphate forms. This conversion causes rapid clearance and a reduced
half-life of the drug up to 15 min [13].
The efficacy of Gemzar as a first-line treatment for pancreatic cancer was done by conducting
clinical studies and comparing Gemzar with 5-Fluoro-Uracil. During the experiment, clinical data
were obtained from 126 patients suffering from pancreatic cancer with significant symptoms. The drug
dose given was either GEM 1000 mg/m2 weekly × 7 followed by 1 week of rest, then weekly × 3 every
4 weeks thereafter (for 63 patients), or 5-FU 600 mg/m2 once weekly (for 63 patients). The expected
result was to alleviate at least one parameter associated with symptoms which could help in increasing
patient survival rates without causing additional side effects. A significant change in survival rate was
observed in 23.8% of patients treated with GEM compared with just 4.8% clinical benefits in patients
under the influence of 5-FU, which concluded the comparatively high therapeutic activity of GEM [14].
2.2. HPMA Copolymer-Based Gemcitabine Formulation
Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) is a copolymer which is widely used to
formulate various anticancer drugs. HPMA copolymer formulation provides prolonged GEM by
utilizing enhanced permeability and retention effects which localizes the drug at the tumor site [15].
The PHPMA-GEM formulation was made in two forms, A-Gemcitabine (A-GEM) and B-Gemcitabine
(B-GEM). A-GEM drug-polymer conjugate was made using uncleavable amino hexanoic acid spacers
whereas B-GEM was formulated using glycyl-phenyl-alanyl-leucyl-glycine (GFLG) spacers with an
ability to get cleaved by lysosomal cysteine protease cathepsin. HPMA formulations were proposed to
be used in conjunction with radiation therapy. Particularly, B-GEM formulation demonstrated a 100%
drug release within 6 h in the presence of radiotherapy and showed much more efficacy than GEM
alone [16].
2.3. Gemlip
GEM suffers from enzymatic inactivation and gets converted to its primary metabolite
2′,2′-difluoro-deoxyuridine (dFdU) in presence of enzyme cytidine deaminase being present abundantly
in the liver and plasma [17]. Gemlip is a liposome-based GEM formulation (hydrogenated egg
phosphatidylcholine/cholesterol) with an equal amount of drug inside and outside the liposomal shell.
Such a composition allows GEM to be present in a constant portion between the vesicle cores and
the aqueous space. This formulation enhanced the half-life of the drug up to 13 h, protecting it from
deamination, increased therapeutic efficacy up to 35-fold more than GEM alone, and decreased the
maximal tolerable dose from 360 to 6–9 mg/kg [18].
2.4. Co-Delivery of Gemcitabine
The use of single chemotherapeutic agents has shown limitations caused by their poor stability
and bioavailability, drug-resistance, and high systemic toxicity. Co-delivery of dual or multiple/cocktail
drugs have come up with synergistic therapeutic action and minimized side effects [19]. Though
GEM is preferred as a first-line treatment for pancreatic cancer, its enzymatic plasma deaminase
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decreases its half-life to 8 to 17 min [20]; that demands an increase in drug-dose which would lead
towards probable side effects. Common side effects associated with GEM include: black/tarry stools or
blood in urine/stools, bleeding gums, swelling of the face and other parts of body, vision issues, chest
pain, cough, diarrhea, dizziness, fever, headache, burning, crawling, itching, numbness, difficulty in
swallowing, joint pain, pale skin, paralysis, ulcers, sore throat, trouble sleeping, tiredness/weakness,
and weight loss [21].
A significant number of literatures is available in PubMed suggesting that co-administration of
GEM with other drugs has vast clinical significance in treating pancreatic cancer (Figure 1).
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Figure 1. Peer-reviewed publications, book chapters, comments, and reviews, related to Gemcitabine
co-administration with various other drugs to treat pancreatic cancer. The number of publications was
obtained from archived data in PubMed (up to December 2018).
Detailed review reports discussing the superiority and complexity of regiments to increase the
overall survival of pancreatic patients are shown in Figure 2A. In addition, Figure 2B suggests a number
of clinical studies supporting combinatorial therapeutic interventions of GEM with other drugs are
promising and can be utilized as newer therapeutic regimens for progression-free survival of PanCa.
Altogether, co-administration of GEM with other drugs (Figure 2) depict several marginal survival
benefits while it may further introduce complexity of toxicity and procedures. Therefore, an additional
and safe way to deliver these GEM drug combinations using nanoparticle-mediated delivery may
serve as a new tool to improve clinical benefits of combination therapy. The nanomedicine approach
enables tumor-specific delivery of the payload while offering minimized systemic or off-target
effects. Therefore, our later sections are aimed at presenting and discussing recent advances in
delivering nanoparticle-mediated multiple drugs to pancreatic tumors in order to achieve superior
therapeutic benefits.
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3. Nano Formulations Involved in Gemcitabine Co-Administration and Co-Delivery
Gemcitabine co-administration with various chemotherapeutic drugs have shown significant
effects and positive utcome at clinical level (Fig re 2) and has lso been p blished extensively [22–24].
However, a comm n problem was obs rved due to the difference in their profiles such as
hydrophilicity-to-hydrophobicity, pharmacokinetics, toxicity, and mod of actions when administered
together with other ugs. The distance of the target site often leads towar s significant drug loss
nd problems related to drug release in a time-contr lled manner. These factors cause a change in
rate ki etics which does not provide th expected drug effect. Therefore, it is important to de ign
drug delivery models which preserve th integrity of the drug and its releas at the targ ted site of
acti n. Thus, successf l delivery of dual/multi drugs to pancreatic tumors is an encouraging path
for developing effective therapeutic r gimens. Id ntifying an effective delivery arrier that does not
i tr duce systemic toxicity is hi hly warranted. At this point, anoparticles come into exist nce as
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carriers for drug molecules [25]. In general, depending on their use, nanoparticles are considered
to be 1–200 nm in dimension. In the medicinal field, nanoparticles are often designed in a way that
drug/bio-molecules can be incorporated within and do not get degraded at undesired sites, which can
help the drug to reach the targeted site of action more efficiently. Often, nanoparticles can improve the
circulation time of the loaded therapeutic molecules and improve its residence at the tumor site through
leaky vasculature by enhancing permeation and retention (EPR) effects [26–29]. Many approved
(paclitaxel albumin-bound nanoformulation (Abraxane®, Celgene) doxorubicin liposomal formulation
(Doxil, currently with Caelyx), micellar formulation of PTX (Genexol-PM, Samyang Biopharm)) and
clinically evaluated nanoformulations obey EPR delivery characteristics [30]. Upon reaching the
targeted site, nanoparticles internalize (the process of endocytosis, phagocytosis, and pinocytosis)
and communicate with cancerous cells [31]. This characteristic avails the drug at a tumor specific
site which avoids the leakage of the drug into normal tissue and decreases the incidence of adverse
side effects [32]. Cellular internalization attained by nanoparticles is generally ligand-mediated, i.e,
expression of certain proteins or receptor are aberrant in cancer cells which are utilized during the
designing of nanoparticles to concentrate the drug at the targeted site, avoiding off-target effects.
Certain receptors which are overexpressed in cancer cells, such as EGFR, GPCR, FR, TFR, etc. [31], can
be used to target more precisely. Thus this section aims to delineate various options of developing
therapeutic nanoformulations for dual/multiple therapeutic molecule delivery to PanCa (Figure 3).
This can be achieved by various means, including but not limited to, altering the chemical composition,
design/sequence, and decoration with targeted motifs and so on [33].
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Figure 3. Different nanoparticle mechanisms of delivering therapeutic agents: (1) nab-PTX causes cell
cycle arrest by inhibiti g polymerization of microtubules during mitosis within recipient cell [34],
(2) nanog l releases the drug within the cell in stimulation to suitable pH and temp rature as the pH
and temperatur of cancer cells are higher than or al cells [35], (3) metal-base magn tic nanoparticle
checks drug resistance by inhibiting and blocking the P-gp drug efflux mechanism when they are
taken up by cancer cells via micropinocytosis, which further obstructs P-gp beca se of t e large size
of the nanoparticles [36], (4) liposomes cross the lipid bilayer to target the cancer cells directed by
biomarkers aberrantly expressed in PanCa [37], and (5) a micelle encapsulated drug acts as a ligand to
target receptors which are specific to GEM-based co-therapy [38].
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Various synthetic approaches, both topdown and bottom-up, of nanocarrier development via
nanoprecipitation, double emulsion, solvent evaporation, self-assembly, layer-by-layer approaches,
polymer micellization, and gelation are suitable with the appropriate engineering surface
chemistry. All these approaches offer pre-determined particle size range and distribution,
hydrophobicity–hydrophilicity balance, porosity, and polymer chain/gel network, drug encapsulation
capacity, sustained/stimuli-responsive drug release as a function of formulation characteristics. Table 1
provides a list of various nanoformulations that can preferably encapsulate two drugs and possess
sustained delivery to induce synergistic activity. The sections below delineate more about various
types of nanosystems that were widely employed for GEM combination delivery.
Table 1. Various types of nanosystems at a pre-clinical step for optimizing and inducing the synegistic
action of drugs in pancreatic cancer.
Nano-Systems Drug Conjugate Characterization Utilization
(Micelles)
GEM-PL
GEM-methoxy poly(ethylene
glycol)-poly(lactic acid)
(GEM-PL)
Particle size 112.2 ± 1.86 nm,
zeta potential, 5.2 ± 1.26,
encapsulation efficiency
92.5 ± 3.26
loading efficiency of
14.6 ± 1.29
and PDI(Poly dispersity
index) 0.118.
In-vitro study was done using
human colon cancer cell line
HT29 and in-vivo studies for
anticancer efficacy was done by
injecting HT29 (5 × 106 cells)
subcutaneously into right flank
per mice and when tumor
volume reached 100 mm3,
5 mg/kg fixed drug dose was
administered 3 times for 12 days.
In-vivo studies depicted
improved blood circulation time
with greater accumulation of the
drug in tumor site with
significant tumor regression.
Formulation killed HT29 cells at
a time dependent manner [39].
This study provides a valid
reason required for further
clinical research.
(Micelles)
C225—micelle-GEM-miR-205
GEM-miR205-EGFR targeting
Cetuximab antibody (C225)
Unmodified micelles
containing GEM and
miR-205 had the size of
76.6 ± 6 nm and zeta
poteintial of 4.7 ± 1.65 mV.
C225 conjugation was
checked with standard BSA
which was found to be
510 µg/mL C255 micelle 30%
w/w for 10 gm polymer.
In-vitro studies were conducted
using MIA PaCa-2 and in-vivo
studies such as biodistribution
and efficacy studies were done
on NSC mice using an
orthotopic tumor model where
mice were implanted with
GFP-transfected MIA PaCa-2
cells. In-vivo studies were
conducted using a orthotopic
pancreatic tumor model in
6 week old NSG mice injected
with GFP transfected MIA
PACA-2 cells [40].
(Micelles)
PHC-GEMC18
poly(ethylene glycol) (PEG)
conjugated hydrophobic
stearic acid derivative (C18)
bonded through acid sensitive
hydrazine bond-GEM
PHC size of 21.6 ± 0.6 nm
zeta of 3.3 ± 1.1 mV
PHC3%(GEM) size of
9.6 ± 3.7 nm zeta of
2.7 ± 1.2 mV
PHC5%(GEM) size of
5.0 ± 0.1 nm zeta of
−2.0 ± 0.7 mV.
PHC10%(GEM) size of
9.7 ± 1.3 nm zeta of
−2.2 ± 0.9 mV.
B16-F10 tumor was grown on
C57BL/6 mice by subcutaneous
inoculation in the right flank
followed by treatment after day
6 of inoculation. As compared to
GEM alone which is because of
the increase in GEM18
accumulation [41].
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Table 1. Cont.
Nano-Systems Drug Conjugate Characterization Utilization
(Micelle)
GE11-PEG-PCD/
mPEG-b-PCC-g-GEM-g-DC
G11 peptide of GEM
conjugated with poly
(ethylene glycol)-block-poly
(2-methyl-2-carboxyl-propylenr
carbonate-graft-Gemcitabine-
graft-dodecanol micelle
Particle size of 26 ± 3 nm
with a polydispersion index
of 0.27 [42].
MIA PaCa-2 cells have been
used for the in-vivo studies and
6–8-week-old athymic nude
mice were used for a orthotopic
pancreatic cancer model for
studying efficacy of the micelles
after intraperitoneal injection of
D-luciferin for bioluminescence
studies. Increase in GEM
delivery was seen up to 2.5 folds
with an enhanced circulation
half-life and EPR effect
facilitating extravasation of
micelle loaded drugs within the
tumor microenvironment [43].
(Micelle)
DTX-PEG-GEM
Docetaxel-Polyethylene-
glycol-GEM
Particle size of
124.2 ± 5.7 nm and PDI of
0.132 ± 0.03 with critial
micelle concentration range
of 5–10 × 10−3 mg/mL.
In-vitro studies were done using
MCF-7 and MDA-MB-231 for
checking cellular internalization
and uptake, In-vivo study used
female Sprague dolly rats for
carrying forward the
pharmacokinetic and toxicity
studies. Clathrin mediated
endocytosis with 4.8 fold higher
AUC value as compared to
Gemzar alone was observed
with a noteworthy decrease in
tumor volume, increase in total
survival, and reduction in
hepatic, nephron, and hemolytic
toxicity when administered with
DTX-PEG-GEM nanoparticles
[44].
(Micelle)
P-GEM-DOX
Poly(HPMA-co-MA-
GFLG-GEM
co-MA-GFLG-DOX-
co-MA-TyrNH2)
Molecular
weight = 23.5 kDa, PD = 1.6,
GEM = 6.4 wt %,
Dox = 5.7 wt %,
tyrNH2 = 1.0 mol %.
Dunning AT1rat prostate
carcinoma cells were used for
the in-vitro studies which
involved drug release,
cytotoxicity, and efficacy study
of the formulation. In-vivo
studies were conducted on male
Copenhagen rats present with
subcutaneous tumor. Enhanced
circulation time with selectivity
and localization at
tumor-specific sites was seen
with induction of apoptosis and
inhibition of angiogenesis.
In-vivo efficacy of P-GEM-DOX
< free GEM, though
co-conjugation enhanced
in vitro efficacy [45].
(Micelle)
GEM-LEMPs-DNA
PEGylated lipid bilayer
cationic ε poly lysine
co-polymer with
GEM-(si-HIF1α)
Particle size of 60 nm with a
hydrodynamic diameter
according to DLS study, size
was 141.8 nm zeta potential
of GEM-LEMP-DNA was
−34 mV, encapsulation
efficiency of 42%.
Serum stability, cytotoxicity,
PCR, and immunohistology
studies were done using Panc-1
and B-16 melanoma cells. The
in-vivo studies were conducted
on female BALB/c mice to check
the antitumor activity of the
formulation. Formulation
caused effecting silencing of
HIF1α via siRNA and reduced
drug-related resistance. The
lipid layer protects si-HIF1 α
from degradation thereby
maintaining the integrity of the
particle and preventing leakage
of GEM [46].
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Table 1. Cont.
Nano-Systems Drug Conjugate Characterization Utilization
(Micelle)
GEM-C18-PLGA-MP
Stearoyl GEM incorporated
within PLGA with surface
functionalization with human
serum albumin
GEMC18 content was found
to be 488.9 ± 35.7 µg/mL
with PLGA content of
1.71 ± 0.21 mg/mL
corresponding to
285 ± 56 µg/mg or
28.6% ± 5.6% (w/w) of
particle matrix, prodrug
release of 13.2% ± 1.8% was
seen after 5 days incubation.
SV-HUCC-1 normal urinary
bladder cell was considered as
control and urothelial cancer cell
line 5637 and HT-1376 were
used for a cell viability assay,
studies for determining
metabolic activity and for
checking the cyto adhesive
properties of formulation.
GEMC18, when conjugated with
PLGA microparticle, avoided
intracellular drug activation
thereby maintaining drug
stability and covalent
modification of the polymer
with human serum albumin, led
towards the enhanced binding
capacity of the formulation with
urothelial cells [47]. In-vivo
studies using an animal model is
still a requirement to confirm the
pharmacokinetics of the
formulation.
(Micelle)
FA-PEG-GEM-NPs
Folic acid conjugated GEM
loaded surface modified
chitosan nanoparticle
Particle size determined to
be 184.3 ± 12.47 nm with a
PDI of 0.22 ± 0.07 zeta
potential of 21.1 ± 1.18 mV
and encapsulation efficiency
of 37.2% ± 2.2%.
In-vivo cytotoxic studies were
done using lung epithelial
cancer cell line A549 for a
cytotoxic assay, drug release and
cellular uptake. Balb/c mice
were used to conduct the
pharmacokinetic study.
Significant cytotoxicity showed
while GEM being delivered
through nano formulation when
treated to A549 cells showed
more effective cellular
internalization than free GEM
[48].
(Metal-based)
IONPs
GEM-siRNA-iron-oxide
nanoparticles Particle size of 80 nm.
Iron oxide was profoundly
conjugated with CD44v6
targeted PanCa and
GEM-siRNA conjugation with
siBmi-1 oncogene to give
multifunctional nanoparticle
scFv-GEM-siBmi-1-NPs an
in vivo anti-tumor synergistic
activity [49].
(Metal-based)
MIL-100 Nano-MOFs
Metal-organic framework of
iron III trimesate
nanoparticles-phosphate GEM
Encapsulation efficiency of
phosphated GEM = 30.7% ±
0.8% which was almost 98%.
GEM-MP loaded NanoMOFs
were studied on PANC-1 cells in
a phosphate devoid medium
with 50% of encapsulated drug
released within 1 min after
administration which stayed for
20 h [50].
(Metal-based)
PS1-EPSMOs-GEM
Tetrasilylated
porphyrin-ethylene periodic
mesoporous organosilica
nanoparticles
PS1-EPSMOs mean diameter
(TEM) = 447 nm, zeta at
pH 5.5 = −30 mV; zeta at
pH 7.4 = −34 mV.
In-vivo delivery of drug was
done on MCF-7 breast cancer
cells. The porous structure
provided high loading capacity
and the addition of the
porphyrin group provided
photosensitivity to the
nanoparticle [51]. In-vivo
studies are yet to be done for
confirming the significance of
this formulation.
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Table 1. Cont.
Nano-Systems Drug Conjugate Characterization Utilization
(Metal-based)
AuNC@BSA-MSN-GEM-DOX
Gold nanocluster bovine
serum albumin clustered with
mesoporous silica added with
32% GEM and DOX combined
with albumin, attached
electrostatically to formulation
Nanoparticle size = 150 nm,
gold-protein conjugate zeta
potential of −38 ± 1 mV for
MSN-AuNC@BSA + DOX
+ GEM with AuNC content
of 2.10 ± 0.23 and BSA
15.90 ± 1.80.
In-vitro study for the
formulation was done using
A549 lung cancer cells and
biodistribution of formulation
was seen in nude mice being
previously injected
subcutaneously with
MIA-PaCa-2. Dual loading of
GEM + DOX was 72 wt % which
was four times higher than
previous reports with less than
4% leakage of the loaded drug
after a week in blood serum [52].
(Metal-based)
PTX-GEM-LB-MSNNP
Lipid layer mesoporous-silica
nanoparticle loaded with PTX
and GEM
Hydrodynamic partilc size
of 101 nm in saline and
112 nm with zeta potential of
of −27.2 mV and −5.4 mV in
saline plus 5% serum
condition.
Cytotoxicity study, expression of
cytidine deaminase and heme
oxygenase via Western blot was
done using PanC-1 cells and for
the in-vitro studies, these cells
were transfected with luciferase
and implanted to grow
subcutaneously within
xenograft nude mice.
Co-delivery of a dual drug
caused enhanced
phosphorylation with an
increase in DNA-GEM
interaction up to 13 fold and
decreasing inactivated
deaminated metabolite up to 4
folds producing synergistic
codelivery of GEM and PTX [53].
(Metal base)
GEM-Au DENPs/miR-21-inh
Ultrasound targeted
microbubble-based dendrimer
entrapped gold
particle-Gemcitabne-miR-21
inhibitor
Mean particle size obtained
was 154–276 nm with a
surface charge range of
11–33 mV.
SW1990 cells were used to check
the effect of the formulation on
cytotoxicity, female athymic
Balb/c mice were used to check
the antitumor activity of the
formulation. Uptake and
apoptosis. The apoptosis
percent of GEM–Au
DENPs/miR-21i group (20.87%
± 0.81%) and GEM–Au
DENPs/miR-21i + U group
(25.43% ± 0.60%) which came up
to be much more than the free
GEM group (10.50% ± 0.56%)
[40].
(Hydrogel)
PNIPAM-b-PNAM-b-PNBOC
poly(N-isopropylacrylamide)-
b-poly (4-acryloyl
morpholine)-b-poly(2-
(2-nitrobenzyl)oxy) carbonyl)
amino)ethyl
methacrylate)-GEM-Doxorubicin
Average hydrodynamic
diameter was determined to
be 68 nm. TEM observation
gave spherical nanoparticles.
Extra micellar aqueous phase
and the hydrophobic micellar
core of formulation helped in the
incorporation of a hydrophilic
and hydrophobic drug [54]. This
work showed the synthesis and
characterization of formulation
which needs follow up with
in-vivo and in-vitro studies.
3.1. Liposomes
Liposomes are the vehicles commonly used for drug delivery applications [55]. Liposomal
integrity consists of the modulation of lipid structure with a hydrophilic head and hydrophobic tail
molecules facing each other in bilayered phospholipids. This is commonly achieved by electrostatic
interaction, hydrogen bonding, and Van der Walls forces, and can be modified in aqueous solution [56].
Liposomes (a size range of 50 to 150 nm) are suitable for drug delivery applications and capable of
the loading of both hydrophilic and hydrophobic drugs within the core of the formulation and the
hydrophobic one between the lipid-based bilayer, respectively. Clinical data on the co-delivery of
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PTX and GEM show synergistic action. However, co-delivery of PTX and GEM is a challenging task
because of the difference in aqueous solubility (PTX is almost insoluble in water) and pharmacokinetic
profiles (Abraxane with a half-life of 27 h, mean total clearance of 15 L/h/m2 and mean volume of
distribution of 632 L/m2, GEM with a half-life of 42–94 min, mean total clearance of 30.7–92.2 L/h/m2
and mean volume of distribution of 50 L/m2) [57,58]. These differences have made it impossible to
deliver both the drugs together in an equal ratio, which is important for their synergistic effect. The
solution to this problem may be a delivery vehicle which can efficiently encapsulate both drugs within
a formulation. Co-encapsulation of dual drugs in the formulation is not always suitable for efficient
and sustained drug release [59,60]. Co-encapsulation of GEM + PTX within a single formulation as
Lipo-PTX-GEM (LpPG) leads to poor drug release because of the hinderance of PTX on GEM where
membrane-bound PTX hinders the diffusion function of the liposome. To overcome this problem,
GEM and PTX were formulated separately as LpP (PTX loaded liposome) and LpG (GEM loaded
liposome) using DPPC, cholesterol, and DSPE-PEG2000 followed by small volume loading method.
Comparative studies were done using LpP and LpG, which provided the synergistic activity of both
drugs when given in a scheduled dose and ratio. PTX-GEM incorporation as LpPG did not provide
adequate drug release and pharmacokinetic profile but cytotoxicity testing on SKOV-3 human ovarian
cancer cells with a separate formulation of LpP and LpG showed better activity. GEM release from
LpPG was 37.9% and that from LpG was 66.1%; therefore, the combination treatment of LpP and LpG
came up to be more effective than LpPG [60]. High drug dose is the responsible factor for off-targeted
cytotoxicity and side effects but Gallo and co-workers, who developed the liposomal-based formulation
of DOX in combination with GEM, showed better circulation and extravasation to the tumor sites
in cisplatin-resistant human ovarian cancer Xeno-grafts(A2780/CDDP) female athymic mice (HSD:
Athymic Nude-nu) thereby confining the drug within the tumor site, which decreases the probability
of drug-related toxicity. Combination treatment with a GEM dose of 20 mg/kg and a Liposomal
DOX dose of 6 mg/kg was assigned for treatment groups (mice) which were compared with mice
under similar GEM monotherapy. All mice receiving this drug combination showed regression in
tumor growth with no growth for 2 months. A further decrease in the drug dose to 10 mg/kg GEM
and 6 mg/kg liposomal DOX treated in two treatment schedules—one with GEM collaterally treated
with DOX-liposome and the other treatment of 24 h GEM treatment proceeded by DOX-liposome
treatment—showed almost similar results as obtained by high GEM dose, which suggested that a
low drug dose can be substituted to avoid toxicity. The actual mechanism involved in the synergistic
activity of GEM + DOX was unclear for the group to depict but targeting different metabolic pathways
may be a reason for consideration for the synergistic activity [61]. EndoTAG-1, a cationic lipid (DOTAP
and DOPC)-based PTX complex, is a conventional agent used in vascular chemotherapeutic targeting;
it was checked for its enhanced anticancer effect in a L3.6pl pancreatic tumor model when combined
with GEM. Groups treated with EndoTAG-1 monotherapy showed a significant reduction in tumor
growth when compared with control and an EndoTAG-1 dose of 5 mg/kg body weight thrice every
week gave the same results as that of a GEM dose of 100 mg/kg body weight twice weekly. When
EndoTAG-1 was combined with GEM, it showed a decrease in tumor growth up to 78% as compared
to control, which further led towards the investigation of a lower dose of GEM. A decrease of the
GEM dose to 50 mg/kg body weight showed decreased antitumor activity to 30% which was again
restored by combining EndoTAG-1 with 50 mg/kg body weight GEM, giving a supra additive effect.
Tumor volume for the group treated with EndoTAG-I + GEM was significantly less than the control
group and the groups with EndoTAG-1 and GEM monotherapy. Inclusive to its antitumor effect, the
combinational treatment decreased the occurrence of liver, lymph node and peritoneal metastasis [45].
Poly(HPMA-co-MA-GFLG-Gemcitabine-co-MA-GFLG-doxorubicin-co-MA-TyrNH2) is a construct of
a HPMA polymer conjugated with 6.4 wt % GEM and 5.7 wt % of DOX with 1 mol.% tyrosinamide
(known as P-GEM-DOX) which exhibited a superior cytotoxicity effect. The efficacy of GEM and DOX
was enhanced using this multi-drug targeting formulation without an increase in its level of toxicity.
Effect of the formulation on tumor growth was compared using a control group where the results
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showed that the formulations with a 50% maximum tolerated dose regimen of P-GEM-DOX showed
a 50% reduced tumor growth and formulation with 75% MTD showed a reduction in the tumor up
to 60%, which was significantly higher than the control group and the groups with a low dose of
P-GEM-DOX. There was no significant decrease in body weight of control group and the group with
a low dose of P-GEM-DOX with a maximum of 5% loss in the body weight of groups treated with
50% and 75% maximum tolerated dose regimens of P-GEM-DOX [45]. In recent years, a fabricated
form of nanoparticles has been much more in use. Thermoresponsive liposomes were introduced
to release drugs at the specific tumor site. These liposomes have a phase transition temperature of
42 ◦C when coated with a suitable polymer which makes the formulation release its therapeutic moiety
only when triggered thermally. The normal body temperature of 37 ◦C does not allow the liposome to
avail the drug at normal cellular environments but mild hyperthermia at the tumor site triggers drug
release at the specific site; therefore, this modulation provides significant drug availability at tumor
sites [45,62]. Layer-by-layer co-loading of gemcitabine and platinum (IV) prodrug nanoparticles were
constructed for synnergestic combination [63]. Similarly, a GEM + Cis-based thermosensitive liposome
was formulated using DPPC/HSPC/Chol/DSPE-PE2000 polymers in a molar ratio of 100/50/30/6 which
favors cellular internalization at 40 ◦C in BxPC-3 and MiaPaCa-2 cancer cells [63,64], thereby decreasing
the off-target effect and systemic toxicity [63]. The reticuloendothelial system (RES) is the main site that
liposomes reach after getting administered, from which they get further cleared out from the system.
RES is also involved with the bodies innate immune system. Therefore, in spite of liposomes being an
important carrier suitable for drug delivery, during the delivery of anti-cancer drugs, liposomes cause
the destruction of macrophages as they are part of the body’s innate immune system—this causes an
imbalance in the immune system leading towards immunosupression and infection [64,65]. Though
liposomes play great role in incorporating dual drugs in the same formulation, helping hydrophobic
drugs surpass the lipid bilayer, there are drawbacks associated in their use as any leakage and fusion
with the lipid bilayer may cause a loss in the amount of drug required at site of action, which may not
provide the desired action. Apart from this, the phospholipids which are used for making liposomes
may undergo oxidation and hydrolysis at altered conditions which could cause a loss of the quality of
formulation [66].
3.2. Nanogels
Nanogels are three-dimensional cross-linked (physical and chemical bonds) network polymeric
structures which can offer drug depot and controlled drug release for targeted drug delivery [67].
Nanogels possess a great tendency of water retention and are biocompatible and biodegradable.
GemC12-LNC is a nanogel-based nanomedicine synthesized using lauryl and GEM as the chief
therapeutic agent. GemC12-LNC is modulated in a way where the lipophilic drug (PTX as a model)
can be incorporated in the oily core whereas the hydrophilic one gets incorporated inside the aqueous
phase. PTXGemC12-LNC treatment to GL261 and 9L cell lines showed its enhanced therapeutic activity
tested through the invasion, proliferation, and the aggressive aspects of cancer [68]. Amphiphilic
block polymers of PNIPAM-b-PNAM-b-PNBOC were used for the formulation of thermo-responsive
hydrogel with a PNBOC polymer to be around 68 nm with a spherical structure to contain the photo
responsive moiety. Being a photo and thermosensitive formulation, it can control the hydrophilic and
hydrophobic drug release. Besides these considerations, the effect of UV light and polymer ratios were
also concerns for the effective drug release of GEM and DOX. Drug release was much higher in the
presence of UV radiation, than in the absence of UV radiation. In higher ratios and concentrations
of polymers, drug release was decreased despite increased UV radiation therefore, it is important
to maintain a constant ratio of PNIPAM-b-PNAM-b-PNBOC in the presence of UV radiation [54].
GEM and cisplatin are standard drugs and widely used for the clinical treatment of cancer. The
problem associated with them is their toxicity and non-targeted effect. Loading Cisplatin within nano
gel formulation (PEG170-b-PMA180 and Mal-PEG-NH2 conjugated with TKH2 antigen, a specific
antigen aberrantly expressed in PanCa) helped in improving the PK of cisplatin. A higher amount of
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platinum reached the cells expressing Sialyl Tn antigen-specific with TKH2-cisplatin nanogel binding.
The dose of cisplatin in GEM 79 combined TKH2-cisplatin hydrogel came up to be 40-fold less than
the dose of cisplatin when used as monotherapy. GEM and TKH2-cisplatin hydrogel when given
as monotherapy was responsive to primary tumor suppression which was further suppressed by
GEM with TKH2-cisplatin hydrogel. The tumor-suppressing effect was better than the non-targeted
formulation of GEM + IgG-cisplatin hydrogel but was not statistically significant enough. A metastatic
check on other organs revealed that there was no significant metastasis to other organs in the groups
treated with GEM + TKH2-cisplatin hydrogels. Therefore, GEM + TKH2-cisplatin hydrogel as a
formulation is an efficient delivery vehicle to sensitize platinum within cancer cells which is guided by
GEM-added combinational therapy and TKH2 antibody conjugation [40]. Use of nanogels have not
only enhanced the delivery of GEM in combination with other drugs but has also helped in generating
other routes of GEM administration. GEM is a drug which is preferably administered through the
IV route as there are limitations to its oral route of administration such as poor GI permeability and
rapid deamination of GEM. Preparation of the polymeric nanogel was done using PVA polymer
grafted with cholesterol and incorporated with GEM by the process of co-evaporation. Mia PaCa-2
and Capan-1 cells were used for in vitro studies and the tumor inhibitory studies were carried out in
tumor xenograft female nu/nu mice model. Nanogel encapsulated GEM and Floxuridine showed 3
to 25 times higher cytotoxicity against PanCa cells than the free drug. A GI permeability check was
also carried using the Caco-2 cell model which showed permeability constant of 7.5 times more for
GEM encapsulated PVA nanogels than GEM alone. Conducted studies showed effective drug release
triggered by enzymatic activity within cancer cells and results from animal experiments. Though the
delivery of chemotherapeutic drugs using nanogels is advancing swiftly because of its ability to be
fabricated according to changes in pH and temperature, the synthesis and removal of solvent during
the formulation is quite expensive and, apart from this, the presence of any monomer or surfactant can
add additional toxicity to the formulation.
3.3. Micelles
Polymeric micelles possess a unique shell-like structure. For drug delivery purposes, micelles are
modified copolymers with a hydrophobic core and a hydrophilic shell. Mondal et al. [40] showed the
impact of an increased GEM dose which leads to GEM-related drug resistance impacting the therapeutic
activity of GEM. GEM and miR-205 have been formulated using PEG-b-PCC-g-GEM-g-DC-g-TEPA
and conjugated with the EGFR targeting Cetuximab antibody. This formulation is efficient to target
GEM at pancreatic tumor sites. Both in vitro studies on MIAPaCa-2 and in vivo studies on MIAPaCa-2
orthotopic mouse models showed enhanced drug uptake in the group treated with formulations
containing Cetuximab as the targeting antibody than the control group. Mice showed low tumor
volume when treated with the GEM-miR-205-Cetuximab conjugated formulation with no alteration in
body weight, suggesting negligible drug-based toxicity [40]. GEM and PTX, being standard therapy
against carcinoma, have faced problems during co-delivery (which has been discussed in previous
sections). An FA-PEG-VE (folic acid and tocopherol conjugated PLGA-based micelles) formulation
demonstrated significant inhibitory effects against A549 cells when GEM-PTX were incorporated.
A more synergistic drug effect was observed in vivo and pharmacokinetic analysis when the formulation
was modified with tocopherol [45]. Though chemotherapy aims to eradicate tumor and cancer cells,
chemotherapy does not function efficiently to eradicate the slow-growing cancer cells also known as
cancer stem cells [69]. The use of mixed micelle-based nanoparticles (PEG-b-PAC and PEG-b-PUC
through hydrogen bonding and ionic interaction) shows a high drug loading capacity with an ability
to incorporate GEM and Phenformin, exhibiting good activity against cancer stem cells [70,71]. The
activity of Lauroyl-GEM (Gem-C12) and honokiol have already been reported as a treatment where
GEM helps in terminating the elongation of DNA chain leading to apoptosis, and honokiol as an
inducer of apoptosis. Thus, nanoparticle formulation of the Gem-C12 and HNK combinational therapy
was able to reach the targeted site of action [72,73]. CD44 can be a useful target in cancer treatment
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because of its aberrant overexpression in cancer cells. Hyaluronic acid (HA) is yet another source which
shows an affinity with CD44 therefore, HA in conjugation with CD44 can be used as a formulation
to avail HA in the tumor-specific site. Formulation of bile salts/phosphatidylcholine mixed micelles
(BS/PC-M)-HA encapsulated with Gem-C12 and HNK utilized the EPR effect to provide drugs to the
targeted cancer cells [74]. Micelles have come up as a great source for co-delivering GEM with other
chemotherapeutic drugs, but micelles have a problem of poor drug loading efficiency, poor structural
stability when used in-vivo, and the micelles themselves are sometimes unable to interact with the
malignant tumor cell and therefore cannot avail the drugs at the targeted site of action [75].
3.4. Albumin Nanoparticles
Albumin bound paclitaxel (Abraxane® or nab-PTX) is a formulation which has overcome the
limitations associated with the paclitaxel drug with a satisfactory solubility in water. Paclitaxel, when
combined with Gemcitabine, has shown an increase in the level of Gemcitabine within tumor cells
by decreasing the activity of cytidine deaminase, an enzyme with an ability to decrease Gemcitabine
metabolism. nab-PTX possesses an ability to distort the stroma of PanCa cells which assist in activating
angiogenesis, thereby increasing circulation, making it easier for GEM to reach targeting sites. Despite
these advantages, this drug combination has shown significant toxicity which demands efficient
studies and trials for drug approval [49]. Phase I and II clinical trials were conducted on GEM and
nab-PTX to determine the maximum tolerated dose of GEM and nab-PTX in treating PanCa, inclusive
of its response towards positron emission scan analysis which helps in determining the alteration
in the pancreatic stroma, influencing drug uptake. Successful clinical trials have fixed a standard
combinational dose of 1000 mg/m2 GEM with 125 mg/m2 of nab-PTX given for a 3-week period in
repetition every 4 weeks. Overall survival, total response rate, and the maximum tolerated dose
obtained from these studies were quite higher. According to their preclinical study, the nab-PTX is
intended for the destruction of the peritumoral desmoplastic stroma, therefore, they increased the
intra-tumoral concentration of GEM within the treated mice group used for their study. Although
these studies gave a direction in using this combination effectively against PanCa, a randomized phase
III clinical trial was much needed to bring up this combinational therapy as an acceptable therapy for
the significant treatment of PDAC [76]. Phase III trials were conducted by employing a total of 861
patients which provided positive data showing greater efficacy of the nab-PTX + GEM combination
over GEM monotherapy. Overall survival was 8.5 months in the nab-PTX + GEM group whereas was
6.7 months in the Gemcitabine group, with a survival rate of 35% in the nab-PTX + GEM group and
22% in the GEM group at one year of drug administration, with 9% in the nab-PTX + GEM group
versus 4% in GEM group after two years of drug administration. The median progression-free survival
was 5.5 months in the nab-PTX + GEM group, as compared with 3.7 months in the Gemcitabine group
with the response rate of 23% in nab-PTX + GEM group versus 7% in the GEM group [77]. OMP-54F28,
used in combination with nab-PTX and GEM on patients with previously untreated stage IV PanCa
had a positive phase I clinical trial (NCT02050178).
3.5. Multifunctional Nanoparticles
Apart from chemotherapy, other types of physical methods (such as hyperthermia, photothermal
therapy) can enhance chemotherapy activity. Hyperthermia plays a vital role in enhancing the
chemotherapeutic efficiency of drugs by alleviating the temperature of cancer cells, and, as a result,
enhancing their sensitivity towards chemotherapeutic drugs. GEM + Cis-based thermosensitive
liposomes have been formulated using DPPC/HSPC/Chol/DSPE-PEG2000 polymers. These liposomes
when modified with polymer to lead to multi-functional nano formulation have a phase transition
temperature of 42 ◦C which makes the formulation release its therapeutic moiety only when triggered
with hyperthermia [64]. The normal body temperature of 37 ◦C does not allow the liposomes to
avail the drug in a normal cellular environment but mild hypothermia at the tumor site triggers drug
release at the specific site; therefore, this modulation provides significant drug availability at tumor
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sites [78]. Non-damaging mild hyperthermia assists as an external stimulus to surpass the cellular
barrier and avail the drug at tumor-targeted sites [79]. Mild hyperthermia and GEM Lip combined
therapy are used where MHT from gold nanorods have been designed in a way to enhance the delivery
of particles with a size less than 100 nm. A 3-fold increased delivery of GEM Lip at the tumor site with
a diameter of 80 nm, MHT with GEM Lip showed a 4-fold reduction in tumor growth which was due
to the enhanced accumulation of GEM within the tumor cells [80]. To enhance the half-life of GEM,
maintain its active metabolite, decrease the dose intake and drug-related toxicity, special carriers are
needed which can enhance overall GEM efficacy [64,81]. GEM-based magneto liposomes have been
formulated as a superior carrier for GEM because it involves the least use of organic solvents during
drug incorporation and is therefore suitable for in vivo applications. Magnetite-based nanoparticles
(DPPC/cholesterol) were also used for encapsulating GEM by the process of coprecipitation. Under
the influence of a magnetic field, the formulation showed 70% drug release after 5 min of exposure.
The formulation had the desired size and zeta potential to be used as a treatment against cancer.
Therefore, magnetic properties of the formulation provided room to enhance temperature at drug
targeting sites which enhances GEM delivery. Techniques which can help to detect the accumulation
of nanoparticles can be important to track down the organ being targeted by the particles, which is
helpful in drug release from nanoparticles. These abilities help in modifying drugs according to the
obtained toxicity and off-target effects [82]. Gadolinium with low molecular weight enhances the
T1 weighed MRI contrast of tissues which makes it easy to image tissues targeted with Gadolinium
as an imaging agent [83]. A formulation containing a combination treatment agent as well as the
imaging agent designed by Li et al. [84] utilizes magnetic resonance to image tumor sites and confine
the GEM drug at image-guided sites, enhancing the retention time of GEM. The formulation came
up as an efficient agent to show significant drug release at the tumor-specific site and MRI helps in
determining the high resolution of tumor sites. Gadolinium, an imaging agent, and GEM, a therapeutic
agent, have been prepared as a self-assembled formulation where the formulation was PEGylated to
enhance its circulation time within the tumor responsive sites. The efficacy of Gadolinium and GEM
loaded nanoparticles showed the highest (72%) tumor inhibition and delay in tumor growth than other
comparative groups. Toxicity studies suggested the neutral nature of the nanoparticles. Therefore,
Gadolinium and GEM-based nanoparticles were efficient enough to inhibit tumor growth, but they
possessed the significant problem of early clearance, which still needs to be addressed [84]. Gold-based
nanoparticles are easy to synthesize with variable shapes and sizes in addition to high biocompatibility
and low toxicity, the surface property of gold nanoparticles can be easily modified and modulated
using targeting moieties [85]. Compared to other imaging agents, gold nanoparticles tend to be a
more effective agent for X-ray which makes them a better agent for CT imaging [86]. Still, there are
limitations added with the benefits of using multipurpose nanoparticles. The tumor microenvironment
provides a major hinderance to the nanoparticles carrying drug cocktails. The physiological barriers
present within the tumor microenvironment such as the dense collagen network, hyper vasculature
and high fluid pressure are the prime sources which hinder the proper circulation and availability of
nanotherapeutics at the targeted site of action [87].
3.6. Targeted Nanoparticles
Nanoparticles have been functionally modified to come up with chemotherapeutic formulations
with significant pharmacokinetic property, non-toxicity, and biocompatibility. Liposomes, solid
nanoparticles, polymer conjugates, micelles and etc. have come up as an emerging source for drug
delivery; but to get established clinically, various trials are still needed for validation. Therefore, in a
broader way liposome and polymeric nanoparticles are the formulations which are being clinically
used for drug delivery in a broad sprectrum of different drug and drug combinations [88]. However,
most of the tabulated and FDA-approved nanoparticle-mediated deliveries primarily rely on the EPR
effect and accumulate in solid tumors due to leaky tumor vasculature. Historically, such delivery
approaches offer the advantage of minimal to medium levels of injected doses of drugs, up to 5 to
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10%. Active targeting mechanisms always exploit and seek safe homing through a target receptor
or membrane protein that typically overexpress on tumor cells. To achieve an increase in tumor
delivery by site-specific and active delivery by attaching active moieties that recognize cancer cells
precisely, such decorative or conjugated nanoformulations have the tumor-homing potential which
can enhance drug distribution in tumors (Figure 4). Mucin is expressed by various epithelial cells,
but when when we talk about PanCa, mucin is abberantly expressed by pancreatic cancer cells which
positively stimulates the growth, proliferation, invasion, and differentiation [89]. This has made mucin
a prospective tumor marker which facilitates the targeting of anticancer therapeutics. MUC13 as tumor
marker in PanCa has been studied [90]. This study demonstrated high MUC13 expression in HPAFII
and Capan-I in PanCa cells compared to normal cells. Data was also presented to show that MUC13
plays significant role in tumor progression by facilitating invasion, metastasis, and cellular motality
with a positive influence of tumorogenic pathways [90]. MUC4 is a class of mucin which, when
expressed during a PanCa condition, caused resistance towards GEM and other neucleoside-based
drugs [91]. Another study involving the targeting of the mucin-based biomarker has been done
as antibody guided GEM targeting by Urey et al. [37] utilizing the Anti-MUC4 antibody and IgG
to formulate iGem Lip which involved covalent linking of the IgG antibody and further coupling
which thiolated anti MUC4 at 1:1000 molar ratio of the IgG present in the formulation. Obtained
results showed significant binding of the iGemLip formulation with MUC4 positive capan-1 cells in a
dose dependent manner when compare with GemLip alone. Cytotoxic studies were also significant
enough to depict enhanced cytotoxity of iGemLip when compared with GemLip and GEM alone.
Therefore, this study brings an impotant targeting-based delivery of GEM using mucin markers but
in vivo studies are still required to provide more concrete evidence for the formulation. Some of
the nanoparticle-based delivery approaches which can be used in a combination with GEM specific
towards receptor targeting are mentioned in Table 2.Pharmaceutics 2019, 11, x FOR PEER REVIEW 17 of 24 
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formulation. 
Table 2. Receptor-based targeting of Gemcitabine-based co-formulation designed using various 
polymers. 
Formulation Target/Ligand Process of Conjugation Outcome 
MPDNCs 
Poly(L-lysine) 
carboxylate 
PTX(PLL-PTX) + 
Hyaluronic acid 
conjugated GEM 
CD44 
Electrostatic attraction 
between PLL-PTX and 
conjugation between HA-
Gem through hydrolysable 
linkers. 
Biliary cancer cells HuCCT1 and SCK 
have been used to check the targeting 
efficiency and therapeutic efficacy of 
the formulation. Xenograft Balb/c nude 
mice were used for checking in vivo 
drug efficacy. Cellular uptake of 
MPDNCs induced synergistic 
apoptosis [92]. 
GEM-AuNPs-
C225 
EGFR 
Incubation of AuNPs with 
2 μg/mL C225 for 1 h at pH 
7.8 proceeded by 1 h 
incubation with GEM 5 
μg/mL. 
Screening of PanCa cells such as 
PANC-1, AsPC-1, and MIA PACA-2 
with EGFR expression enhanced the 
targeting efficiency of formulation 
with a significant reduction in cell 
proliferation and tumor growth in 
orthotopic nude mice injected with 
GFP transfected AsPC-1 cells [93]. 
EM-gold 
nanoparticle 
Plectin-1 
Pyrimidine group within 
GEM provides free NH2 
group where Gem has an 
ability to bind with the 
gold nanoparticle via 
electrostatic force of 
interaction. 
Surface modulated GNPs with 
peptides used for plectin 1 targeting 
and conjugation with GEM showed 
higher cytotoxicity in AsPC-1 and 
PANC-1 cell lines with a significant in 
vivo antitumor efficacy of formulation 
when given via tail vein in female 
Balb/c mice with xenografted 
pancreatic tumor [94]. 
ATF-IONP-GEM 
(Amino terminal 
fragment-iron 
oxide 
nanoparticle-
GEM) 
Urokinase 
plasminogen 
activator 
receptor 
Iron oxide nanoparticle are 
conjugated with amino 
terminal fragment peptide 
of uPA receptor domain 
through lysosomal 
cleavable tetra peptide 
linker. 
In vitro studies to check drug 
cytotoxicity, drug targeting in PanCa 
cells was done using MIA PaCa-2. The 
anti-tumor activity was checked in-
vivo with the help of MIA-PaCa-2 
implanted xenograft model in nude 
mice. Drug dose given twice weekly. 
Endocytosis through receptor-
mediated approach enabled the release 
Figure 4. Passive (EPR) and active (ligand/receptor-based) targeting of Gemcitabine-based
co-formulation.
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Table 2. Receptor-based targeting of Gemcitabine-based co-formulation designed using various
polymers.
Formulation Target/Ligand Process of Conjugation Outcome
MPDNCs
Poly(l-lysine)
carboxylate
PTX(PLL-PTX) +
Hyaluronic acid
conjugated GEM
CD44
Electrostatic attraction
between PLL-PTX and
conjugation between
HA-Gem through
hydrolysable linkers.
Biliary cancer cells HuCCT1 and
SCK have been used to check the
targeting efficiency and
therapeutic efficacy of the
formulation. Xenograft Balb/c
nude mice were used for
checking in vivo drug efficacy.
Cellular uptake of MPDNCs
induced synergistic
apoptosis [92].
GEM-AuNPs-C225 EGFR
Incubation of AuNPs
with 2 µg/mL C225 for
1 h at pH 7.8 proceeded
by 1 h incubation with
GEM 5 µg/mL.
Screening of PanCa cells such as
PANC-1, AsPC-1, and MIA
PACA-2 with EGFR expression
enhanced the targeting efficiency
of formulation with a significant
reduction in cell proliferation
and tumor growth in orthotopic
nude mice injected with GFP
transfected AsPC-1 cells [93].
EM-gold nanoparticle Plectin-1
Pyrimidine group within
GEM provides free NH2
group where Gem has an
ability to bind with the
gold nanoparticle via
electrostatic force of
interaction.
Surface modulated GNPs with
peptides used for plectin 1
targeting and conjugation with
GEM showed higher
cytotoxicity in AsPC-1 and
PANC-1 cell lines with a
significant in vivo antitumor
efficacy of formulation when
given via tail vein in female
Balb/c mice with xenografted
pancreatic tumor [94].
ATF-IONP-GEM (Amino
terminal fragment-iron
oxide nanoparticle-GEM)
Urokinase
plasminogen
activator receptor
Iron oxide nanoparticle
are conjugated with
amino terminal fragment
peptide of uPA receptor
domain through
lysosomal cleavable tetra
peptide linker.
In vitro studies to check drug
cytotoxicity, drug targeting in
PanCa cells was done using MIA
PaCa-2. The anti-tumor activity
was checked in-vivo with the
help of MIA-PaCa-2 implanted
xenograft model in nude mice.
Drug dose given twice weekly.
Endocytosis through
receptor-mediated approach
enabled the release of GEM
within the cells which helped in
intensifying MRI of the tumor
and the presence of lysosomal
cleavable bonds prevented the
formulation from enzyme-based
degradation [95].
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Table 2. Cont.
Formulation Target/Ligand Process of Conjugation Outcome
GEM-Chitosan-
Carbopol-MNPs Folate receptor
Surface conjugation of
Poly acrylic acid polymer
with chitosan forming
multilayer shell with a
surface conjugation with
folic acid.
PLC-PRF-5, DLD-1, and
MDA-231 cell line respective to
different cancers were used to
carry on the in-vitro studies to
depict cytotoxic activity of the
formulation. Additional studies
were also conducted to check for
folate expression within cell.
Targeting of folate receptor
increased the chance of particles
to surpass the cell membrane
and make GEM available at
tumor sites [96]. This study
requires animal work for further
validation of the formulation.
Gem targeted
TGFβi-MSNP β-Kinase receptor
Co-precipitation method
involved. PEI coating
above the MSNP provide
great number of
non-complex hydrogens
which gets attached to
the nitrogen atom
present in TGF B
inhibitor LY364947 via
hydrogen bonding.
Endothelial cells, human
microvascular endothelial cells
and human smooth muscle cells
were used to mimic stromal
environment and BxPC3 cancer
cells were used for in-vitro
studies and for implanting mice
xenograft. Tumor bearing mice
were injected IV. Formulation
decreased vascular pericyte
coverage by inhibiting TGF β
pathway which is caused by
LY364947 group of the
formulation thereby enhancing
efficient uptake of GEM-based
IV liposomal formulation
coming up as a two-way drug
delivery approach [97].
GEM-C18-PEG-DSPE/TPGS EGF-receptor
Stearic acid conjugated
with GEM further been
incorporated within
PEG-DSPE/TPGS
micelles where GEMC18
loaded micelles where
prepared using solvent
evaporation.
Human BxPC-3 were used to
check the proliferation and
cellular uptake of the
formulation. Antitumor and
pharmacokinetic studies were
performed on mice injected with
BxPC-3 intraperitoneally in the
right flank. Formulation
avoided GEM deamination
which was noticed in free GEM
leading towards enhanced GEM
circulation time and 3-fold
increased GEM concentration in
tumor cells [96].
Pharmaceutics 2019, 11, 574 19 of 25
Table 2. Cont.
Formulation Target/Ligand Process of Conjugation Outcome
(GMP + VEGF)-LCP-AA Sigma receptor
Phosphate group present
in GEM interacts with
calcium during the
preparation of micro
emulsion leading
towards encapsulation of
GEM and VEGF siRNA
with a surface
modification with PEG
which increases particle
retaining time within
body.
30–40% greater tumor inhibition
with 8-fold reduced proliferation
and decreased tumor
microvessel density as
compared to alone VEGF and
GEM treatment was observed in
H460 tumor induced mice with
treatment given as IV injection,
in vitro cytotoxic studies
conducted using H460
non-small lung cancer cell.
Multiple nucleic acid
incorporation and targeting of
sigma receptors found
extensively on overexpressing
cells [98].
Folic acid conjugated
GEM loaded chitosan
nanoparticle
Folate receptor
Normal conjugation and
centrifugation process
were utilized in synthesis
of FA-conjugated and
PEGylated GEM-NPs.
Significant cytotoxicity showed
while GEM being delivered
through nanoformulation when
treated to A549 cells showed
effective cellular internalization
than free GEM. Balb/c mice were
used to conduct the
pharmacokinetic study with
formulation injected through
lateral tail vein [48].
4. Conclusions and Future Perspectives
Co-delivery mechanisms with GEM can be an effective tool for enhancing the survival rate
of PanCa patients and decreasing the problems associated with dual drug co-administration. The
recent research conducted with the co-delivery of GEM has shown promising outcomes such as the
ability to decrease individual drug doses, incorporating drugs of different physicochemical properties
together, which warrants further investigation. Although there are certain limitations with co-delivery
techniques such as overcoming the barrier of the physical/chemical features of two different types
of specific drugs or therapies when applied together, it is imperative to find alternative solutions to
improve the efficacy of the combination. Also, uniform drug loading capacity, the stability of the
drug combination, and higher uptake capabilities should also be taken into account. The availability
of various drug delivery options has opened up scope to work on the approach of how the delivery
vehicle can be fabricated in a better way to limit the curbs associated with the delivery of GEM with
other drug cocktails. Combining both hydrophilic and hydrophobic drugs into a single system can
prove to be an efficient technique for the treatment of PanCa patients. Based on the current research
and success profiles of various co-delivery techniques, significant GEM-based co-delievry formulations
based on polymeric micelle has been noticed; therefore, further work on these nanocarriers could help
to promote polymeric micelles as an excellent source of GEM-based co-delivery. This can also help in
designing polmeric carriers in such a way that it can have the properties of different carriers altogether
such as liposome and hydrogel properties within itself, which can make polymeric micelles more
efficient in delivering GEM and other drugs; therefore, these carriers could be nearer to clinical trials
than the other carriers which are being studied now although more advanced studies are required in
this direction to reduce the limitations which are still present with the different nanocarriers, which
would possibly enable more concrete findings to proceed to clinical trials.
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CIS Cisplatin
OXA Oxaliplatin
IRN Irinotecan
ERL Erlotinib
CAP Capecitabine
DOX Doxorubicin
LEU Leucovorin
MIT Mitomycin
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